Bc Carleton

Summary

Country: Canada

Publications

  1. pmc Beta-blocker use and COPD mortality: a systematic review and meta-analysis
    Mahyar Etminan
    Therapeutic Evaluation Unit, British Columbia Provincial Health Services Authority, Vancouver, Canada
    BMC Pulm Med 12:48. 2012
  2. ncbi request reprint Paediatric adverse drug reaction reporting: understanding and future directions
    Bruce C Carleton
    Faculty of Pharmaceutical Sciences, University of British Columbia, Canada
    Can J Clin Pharmacol 14:e45-57. 2007
  3. doi request reprint Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals
    Bc Carleton
    Pharmaceutical Outcomes Programme, Children s and Women s Health Centre of British Columbia, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada
    Pharmacoepidemiol Drug Saf 18:713-21. 2009
  4. doi request reprint Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations
    B Carleton
    Department of Paediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
    Clin Pharmacol Ther 88:757-9. 2010
  5. doi request reprint Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study
    Mahyar Etminan
    Center for Clinical Epidemiology and Evaluation, Vancouver General Hospital, Vancouver, British Columbia, Canada
    J Clin Neurosci 15:576-7. 2008

Collaborators

Detail Information

Publications5

  1. pmc Beta-blocker use and COPD mortality: a systematic review and meta-analysis
    Mahyar Etminan
    Therapeutic Evaluation Unit, British Columbia Provincial Health Services Authority, Vancouver, Canada
    BMC Pulm Med 12:48. 2012
    ..Currently, no systematic review has examined the impact of beta-blockers on mortality in COPD...
  2. ncbi request reprint Paediatric adverse drug reaction reporting: understanding and future directions
    Bruce C Carleton
    Faculty of Pharmaceutical Sciences, University of British Columbia, Canada
    Can J Clin Pharmacol 14:e45-57. 2007
    ..95% of ADRs are likely not reported, less than 25% of marketed drugs can be advertised as safe and effective in children; yet over 50% of Canadian children receive prescription drugs annually...
  3. doi request reprint Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals
    Bc Carleton
    Pharmaceutical Outcomes Programme, Children s and Women s Health Centre of British Columbia, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada
    Pharmacoepidemiol Drug Saf 18:713-21. 2009
    ..The genotype-specific approaches to therapy in childhood (GATC) national ADR network was established to identify specific ADRs and to improve drug safety through identification of predictive genomic biomarkers of drug risk...
  4. doi request reprint Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations
    B Carleton
    Department of Paediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
    Clin Pharmacol Ther 88:757-9. 2010
    ....
  5. doi request reprint Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study
    Mahyar Etminan
    Center for Clinical Epidemiology and Evaluation, Vancouver General Hospital, Vancouver, British Columbia, Canada
    J Clin Neurosci 15:576-7. 2008
    ..A time-dependent Cox model was used to estimate adjusted rate ratios for users and non-users of NSAIDs. The results of our study did not show a protective effect of NSAIDs for PD (rate ratio 0.84, 95% CI 0.81-1.09)...